

REMARKS

Reconsideration of this application is respectfully requested.

Claims 569-717, 719-869, 871-1021, 1023-1173, 1175-1294, 1296-1407, 1409-1568, 1570-1612 and 1614-1727 were previously pending in this application. Replacement claims 1700-1711 have been entered above. New claims 1728-1738 have been added. No claims have been canceled. Accordingly, claims 569-717, 719-869, 871-1021, 1023-1173, 1175-1294, 1296-1407, 1409-1568, 1570-1612 and 1614-1738 as amended and added above are being presented for further examination on the merits in this application.

Applicants have amended independent claims 1700-1711 which are directed to processes carried out using chelating compounds or chelating components. These claims were previously amended in Applicants' March 9, 2001 Amendment Under 37 C.F.R. §1.115 (In Response To The January 30, 2001 Office Action). In the January 30, 2001 Office Action (page 4, full paragraph), it was stated:

Claims 1700-1711 are vague and indefinite for a similar reason as the above claims. In these claims chelating nucleotide analogs are described but without clarifying the radioactive presence as being in the metal that is chelated. For example, in claim 1700, lines 3-13, chelating compounds or components are described but without indicating the presence or absence of a radioactive metal. It is noted that chelating compounds or components do not necessarily actually contain a chelated metal. They may be and usually are prepared without the metal presence which is only added later during a radioactive labeling step. Clarification via clearer claim wording is requested in order to clearly word the claims to correspond to the chelating-metal practice in the specification.

Applicants wish to clarify the nature of their claimed processes when chelating compounds or chelating components are used in the modification of their disclosed detectable modified or labeled nucleotides or nucleotide analogs. Detection of the metal or metal ion chelated by the chelating compounds or chelating components can be carried out radioactively or non-radioactively. Such is disclosed in the specification on page 82:

Of special importance and significance in the practices of this invention is the utilization of self-signaling or self-indicating or self-detecting nucleic acids, particularly such nucleic acids which are capable of being incorporated into double-stranded DNA and the like. Such self-signaling or self-detecting nucleic acids can be created by covalently attaching to an allylamine substituent making up a modified nucleotide in accordance with this invention a molecule which will chelate specific ions, e.g. heavy metals, rare earths, etc. In general, the chelated ion can be detected either (a) by radioactive emission or (b) by using the ion to catalyze a chromogenic or fluorogenic reaction.

In light of the disclosure cited above, Applicants have amended each of claims 1700-1711 to recite that the chelating compound or chelating components are capable of chelating a "metal or metal ion and providing a detectable signal." Reference to "radioactive" has been deleted from claims 1700-1711 to reflect the broader nature of Applicants' disclosure on page 82. To illustrate, the first and third steps in process claim 1700 have been amended thusly. The first process step in claim 1700 now reads in part "providing or generating non-radioactive labeled nucleic acid fragments, . . . wherein each of said fragments comprises one or more detectable non-radioactive modified or labeled nucleotides or nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, wherein said detectable non-radioactive modified or labeled nucleotides or nucleotide analogs comprise one or more chelating compounds or

chelating components capable of chelating a metal or metal ion and providing a detectable signal, and wherein said one or more detectable non-radioactive modified or labeled nucleotides or nucleotide analogs have been modified or labeled on at least one of the sugar moiety, the sugar analog, the phosphate moiety, the phosphate analog, the base moiety, or the base analog thereof. The third and last step of process claim 1700 recites "detecting the presence of each of said separated or resolved fragments by means of the detectable signal provided by a metal or metal ion chelated by said chelating compounds or chelating components in the detectable non-radioactive modified or labeled nucleotides or nucleotide analogs, and determining the sequence of said nucleic acid of interest."

Similar changes have been made to the other independent chelation claims 1701-1711. With respect to the latter, claim 1711, the term "phosphate moiety" was inadvertently recited twice. The second occurrence has been properly changed to "phosphate analog."

As required under the new Simplified Amendment Practice. Replacement paragraphs/sections/claims to be used. 37 CFR 1.121, as set forth in the Changes to the Patent Rules (37 CFR 1.121 MPEP Bookmark, Volume 1, Issue 3), a marked-up version of claims 1700-1711 is attached as Exhibit A. This marked-up version is entitled "Version With Markings To Show Changes Made."

In addition to the amendments to the previously pending claims, Applicants have also added new claims 1728-1738, largely to reflect both the radioactive and non-radioactive nature of their claimed chelation processes. New claims 1728-1732 recite as Markush members the various detectable signals that are provided

or carried out. These include radioactive means, chromogenic means, fluorogenic means, fluorescent means, electron dense means and magnetic means. These various Markush members are supported by above cited disclosure (page 82, full paragraph) from the specification. In addition, the Markush members for fluorescent means, electron dense means and magnetic means are found in the specification, beginning with the last three lines on page 96, and continuing on page 97:

. . . The Sig moiety could also contain a fluorescing component, such as fluorescein or rhodamine or dansyl. If desired, the Sig moiety could include a magnetic component associated or attached thereto, such as magnetic oxide or magnetic iron oxide, which would make the nucleotide or polynucleotide containing such a magnetic-containing Sig moiety detectable by magnetic means. The Sig moiety might also include an electron dense component, such as ferritin, so as to be available by observation. . .

New dependent claim 1733 recites "wherein said detecting step, the chelating compounds or chelating components have chelated a metal or metal ion selected from the group consisting of heavy metals and rare earth metals." Support for the Markush group of "heavy metals and rare earth metals" is also found in the above-quoted page 82, first paragraph (. . . "a molecule which will chelate specific ions, e.g. heavy metals, rare earths, etc.). Claim 1734 depends from the aforementioned claim 1733 and it recites that the "heavy metal comprises cobalt." Support for the heavy metal copper is drawn from the specification, page 83, fourth and fifth lines from the bottom of the page ("Cobalt or other heavy metal ions or other rare earth ions can be chelated . . .").

New claim 1735 recites that the "detecting step is carried out radioactively." Radioactive detection, emissions, isotopes and the like are described variously in the specification, including, for example, in the above-quoted page 82, first paragraph. See also page 84, last paragraph which discloses:

With respect to its use in radioactivity, it can be used to tailor the isotope needed, i.e. if a weak or strong β or γ emitter is needed, that isotope can be chelated. Examples of isotopes that can be used are listed immediately hereinafter.

See also page 97, first paragraph ("The Sig moiety could also include a radioactive isotope component, such as radioactive cobalt, making the resulting nucleotide observable by radiation detecting means.").

New claim 1736 depends from claim 1735 and recites "wherein said radioactive detection is carried out by means of an isotope." Support is taken from any of the portions cited above in support of claim 1735. The same applies for new claim 1737 ("wherein said isotope is a β or γ emitter."). Finally, new claim 1738 provides a Markush listing of isotopes used in radioactive detection. These include bismuth-206, bismuth-207, cobalt-60, gadolinium-153, strontium-90 and yttrium-90. These isotopes are taken from the list of isotopes found on page 85.

Entry of the above amendments and the new claims is respectfully requested.

* * * * *

Dean L. Engelhardt, et al.

Serial No.: 08/486,069

Filed: June 7, 1995

Page 38 [Second Supplemental Amendment (Following Applicants' June 14, 2001
Amendment For The Purpose Of Claim Consolidation) - July 12, 2001]


SUMMARY AND CONCLUSIONS

Claims 569-717, 719-869, 871-1021, 1023-1173, 1175-1294, 1296-1407, 1409-1568, 1570-1612 and 1614-1738 are presented for further examination in this application. Of these, replacement claims 1700-1711 have been entered as amendments above and new claims 1728-1738 have been added.

The fee for adding new claims 1728-1738 is \$738 based upon the presentation of 41 additional new claims [41 claims X \$18 = \$738]. The U.S. Patent and Trademark Office is hereby authorized to charge the requisite \$738 claim fee to Deposit Account No. 11-0035. No other fee or fees are believed due in connection with this Second Supplemental Amendment. In the event that any other fee or fees are due, however, authorization is hereby given to charge the amount of any such fee or fees to Deposit Account No. 11-0035, or to credit any overpayment thereto.

If a telephone conversation would further the prosecution of the present application, Applicants' undersigned attorney request that he be contacted at the number provided below.

Respectfully submitted,



Ronald C. Fedus

Registration No. 32,567

Attorney for Applicants

ENZO DIAGNOSTICS, INC.
c/o ENZO BIOCHEM, INC.
527 Madison Avenue, 9th Floor
New York, New York 10022
Telephone: (212) 583-0100
Facsimile: (212) 583-0150

MARKED-UP VERSION OF THE AMENDED CLAIMS

Exhibit A [Second Supplemental Amendment (Following Applicants' June 14, 2001 Amendment For The Purpose Of Claim Consolidation) -- July 12, 2001]

1700. (Twice Amended) A process for determining the sequence of a nucleic acid of interest, comprising the steps of:

providing or generating non-radioactive labeled nucleic acid fragments, each fragment comprising a sequence complementary to said nucleic acid of interest or a portion thereof, wherein each of said fragments comprises one or more detectable non-radioactive modified or labeled nucleotides or nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, wherein said detectable non-radioactive modified or labeled nucleotides or nucleotide analogs comprise one or more chelating compounds or chelating components capable of chelating a [~~radioactive~~] metal or metal ion and providing a detectable [~~radioactive~~] signal, and wherein said one or more detectable non-radioactive modified or labeled nucleotides or nucleotide analogs have been modified or labeled on at least one of the sugar moiety, the sugar analog, the phosphate moiety, the phosphate analog, the base moiety, or the base analog thereof;

subjecting said labeled fragments to a sequencing gel to separate or resolve said fragments; and

detecting the presence of each of said separated or resolved fragments by means of the detectable [~~radioactive~~] signal provided by a [~~radioactive~~] metal or metal ion chelated by said chelating compounds or chelating components in the detectable non-radioactive modified or labeled nucleotides or nucleotide analogs, and determining the sequence of said nucleic acid of interest.

Filed: June 7, 1995

Marked-Up Version Of The Amended Claims

Page 2 [Exhibit A To Second Supplemental Amendment (Following Applicants'

June 14, 2001 Amendment For The Purpose Of Claim Consolidation)

-- July 12, 2001]

1701. (Thrice Amended) A process for determining the sequence of a nucleic acid of interest, comprising the steps of:

providing or generating detectable non-radioactive labeled nucleic acid fragments, each fragment comprising a sequence complementary to said nucleic acid of interest or to a portion thereof, wherein each of said fragments comprises one or more detectable non-radioactive modified or labeled nucleotides or nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, wherein said detectable non-radioactive modified or labeled nucleotides or nucleotide analogs comprise one or more chelating compounds or chelating components capable of chelating a ~~[radioactive]~~ metal or metal ion and providing a detectable ~~[radioactive]~~ signal, and wherein said one or more detectable non-radioactive modified or labeled nucleotides or nucleotide analogs have been modified or labeled on at least one of the sugar moiety, the sugar analog, the phosphate moiety, the phosphate analog, the base moiety, or the base analog thereof;

introducing or subjecting said fragments to a sequencing gel;

separating or resolving said fragments in said sequencing gel; and

detecting each of the separated or resolved fragments by means of the detectable ~~[radioactive]~~ signal provided by a ~~[radioactive]~~ metal or metal ion chelated by said chelating compounds or chelating components in the detectable non-radioactive modified or labeled nucleotides or nucleotide analogs, and determining the sequence of said nucleic acid of interest.

Filed: June 7, 1995

Marked-Up Version Of The Amended Claims

Page 3 [Exhibit A To Second Supplemental Amendment (Following Applicants'
June 14, 2001 Amendment For The Purpose Of Claim Consolidation)
-- July 12, 2001]

1702. (Thrice Amended) A process for determining the sequence of a nucleic acid of interest, comprising the steps of:

providing or generating detectable non-radioactive labeled nucleic acid fragments, each fragment comprising a sequence complementary to said nucleic acid of interest or to a portion thereof, wherein each of said fragments comprises one or more detectable non-radioactive modified or labeled nucleotides or nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, wherein said detectable non-radioactive modified or labeled nucleotides or nucleotide analogs comprise one or more chelating compounds or chelating components capable of chelating a [~~radioactive~~] metal or metal ion and providing a detectable [~~radioactive~~] signal, and wherein said one or more detectable non-radioactive modified or labeled nucleotides or nucleotide analogs have been modified or labeled on at least one of the sugar moiety, the sugar analog, the phosphate moiety, the phosphate analog, the base moiety or the base analog thereof;

[~~radioactively~~] detecting with a sequencing gel the detectable non-radioactive labeled nucleic acid fragments by means of a [~~radioactive~~] metal or metal ion chelated by said chelating compounds or chelating components; and determining the sequence of said nucleic acid of interest.

Filed: June 7, 1995

Marked-Up Version Of The Amended Claims

Page 4 [Exhibit A To Second Supplemental Amendment (Following Applicants'
June 14, 2001 Amendment For The Purpose Of Claim Consolidation)
-- July 12, 2001]

1703. (Thrice Amended) A process for determining the sequence of a nucleic acid of interest, comprising the step of detecting with a sequencing gel one or more detectable non-radioactive labeled nucleic acid fragments comprising a sequence complementary to said nucleic acid of interest or to a portion thereof, wherein each of said fragments comprises one or more detectable non-radioactive modified or labeled nucleotides or nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, wherein said detectable non-radioactive modified or labeled nucleotides or nucleotide analogs comprise one or more chelating compounds or chelating components capable of chelating a ~~[radioactive]~~ metal or metal ion and providing a detectable ~~[radioactive]~~ signal, and wherein said one or more detectable non-radioactive modified nucleotides or nucleotide analogs have been modified or labeled on at least one of the sugar moiety, the sugar analog, the phosphate moiety, the base moiety or the base analog thereof.

1704. (Thrice Amended) A process for determining in a sequencing gel the presence of nucleic acid fragments comprising a sequence complementary to a nucleic acid sequence of interest or a portion thereof, said process comprising the steps of:

(A) providing

(i) one or more detectable non-radioactive chemically modified or labeled nucleotides or nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into a nucleic acid, or

Filed: June 7, 1995

Marked-Up Version Of The Amended Claims

Page 5 [Exhibit A To Second Supplemental Amendment (Following Applicants'

June 14, 2001 Amendment For The Purpose Of Claim Consolidation)

-- July 12, 2001]


(ii) one or more oligonucleotides or polynucleotides comprising at least one of said detectable non-radioactive chemically modified or labeled nucleotides or nucleotide analogs; or

(iii) both (i) and (ii);

wherein said detectable non-radioactive chemically modified or labeled nucleotides or nucleotide analogs (i) and said oligonucleotides and polynucleotides (ii) are capable of attaching to or coupling to or incorporating into or forming one or more nucleic acid fragments, wherein said detectable non-radioactive chemically modified or labeled nucleotides or nucleotide analogs comprise one or more chelating compounds or chelating components capable of chelating a [~~radioactive~~] metal or metal ion and providing a detectable [~~radioactive~~] signal, and wherein said detectable non-radioactive chemically modified or labeled nucleotides or nucleotide analogs have been modified non-disruptively or disruptively on at least one of the sugar moiety, the sugar analog, the phosphate moiety, the phosphate analog, the base moiety or the base analog thereof; and;

(B) incorporating said one or more detectable non-radioactive chemically modified or labeled nucleotides or nucleotide analogs (i) or said one or more oligonucleotides or polynucleotides comprising at least one of said detectable non-radioactive chemically modified or labeled nucleotides (ii), or both (i) and (ii), into said one or more nucleic acid fragments, to prepare detectable non-radioactive labeled fragments, each such fragment comprising a sequence complementary to said nucleic acid of interest or to a portion thereof, said detectable non-radioactive labeled fragments further comprising one or more detectable non-radioactive chemically modified nucleotides or nucleotide analogs selected

from the group consisting of:



wherein B represents a purine moiety, a 7-deazapurine moiety, a pyrimidine moiety, or an analog of any of the foregoing, and B is covalently bonded to the C1'-position of the sugar moiety or sugar analog, provided that whenever B is a purine, a purine analog, a 7-deazapurine moiety or a 7-deazapurine analog, the sugar moiety or sugar analog is attached at the N9 position of the purine moiety, the purine analog, the, 7-deazapurine moiety or the 7-analog thereof, and whenever B is a pyrimidine moiety or a pyrimidine analog, the sugar moiety or sugar analog is attached at the N1 position of the pyrimidine moiety or the pyrimidine analog;

wherein A comprises at least three carbon atoms and represents at least one component of a signalling moiety comprising a chelating compound or chelating component capable of chelating a [radioactive] metal or metal ion and providing directly or indirectly a detectable [radioactive] signal; and

wherein B and A are covalently attached directly or through a linkage group,
and

Filed: June 7, 1995


Marked-Up Version Of The Amended Claims

Page 7 [Exhibit A To Second Supplemental Amendment (Following Applicants'


June 14, 2001 Amendment For The Purpose Of Claim Consolidation)

-- July 12, 2001]

wherein x comprises a member selected from the group consisting of:




wherein y comprises a member selected from the group consisting of:



wherein z comprises a member selected from the group consisting of
H- and HO-

(ii)



wherein

PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a base moiety or base analog, and

Enz-5(D8)(C2)

Sig is a signaling moiety comprising a chelating compound or chelating component capable of chelating a [radioactive] metal or metal ion and providing a detectable [radioactive] signal, and wherein said PM is covalently attached to SM, said BASE is covalently attached to SM, and Sig is covalently attached to SM directly or through a linkage group; and

(iii)

Sig—PM—SM—BASE

wherein

PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a base moiety or base analog,

Sig is a signaling moiety comprising a chelating compound or chelating component capable of chelating a [radioactive] metal or metal ion and providing a detectable [radioactive] signal; and

wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to PM directly or through a linkage group;

- (C) transferring or subjecting said labeled fragments to a sequencing gel;
- (D) separating or resolving said labeled fragments; and
- (E) detecting directly or indirectly the presence of said labeled

Filed: June 7, 1995

Marked-Up Version Of The Amended Claims


Page 9 [Exhibit A To Second Supplemental Amendment (Following Applicants'
June 14, 2001 Amendment For The Purpose Of Claim Consolidation)
-- July 12, 2001]

fragments by means of a [~~radioactive~~] metal or metal ion chelated by said chelating compounds or chelating components.

1705. (Twice Amended) A process for detecting a nucleic acid of interest in a sample, which process comprises the steps of:

(a) specifically hybridizing said nucleic acid of interest in the sample with one or more oligo- or polynucleotides, each such oligo- or polynucleotide being complementary to or capable of hybridizing with said nucleic acid of interest or a portion thereof, wherein said oligo- or polynucleotides comprise one or more detectable non-radioactive modified or labeled nucleotides or nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, and wherein said detectable non-radioactive modified or labeled nucleotides or nucleotide analogs are selected from the group consisting of:

(i) a nucleotide or nucleotide analog having the formula



wherein


PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a pyrimidine, a purine or a 7-deazapurine base moiety or a base analog of any of the foregoing; and

Sig is a signaling moiety comprising a chelating compound or component capable of chelating a [~~radioactive~~] metal or metal ion and providing a detectable [~~radioactive~~] signal, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to BASE directly or through a linkage group at a position other than the C5 position when BASE is a pyrimidine moiety or an analog thereof, at a position other than the C8 position when BASE is a purine moiety or an analog thereof and at a position other than the C7 position when BASE is a 7-deazapurine moiety or an analog thereof, and such covalent attachment does not substantially interfere with double helix formation or nucleic acid hybridization;

- (ii) a nucleotide or nucleotide analog having the formula



wherein

PM is a phosphate moiety or phosphate analog,


SM is a sugar moiety or sugar analog,

BASE is a base moiety or base analog, and

Sig is a signaling moiety comprising a chelating compound or component capable of providing chelating a [~~radioactive~~] metal or metal ion and a detectable [~~radioactive~~] signal, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to SM directly or through a linkage

group and such covalent attachment does not substantially interfere with double helix formation or nucleic acid hybridization; and

(iii) a nucleotide or nucleotide analog, said nucleotide having the formula



wherein

PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a base moiety or base analog, and

Sig is a signaling moiety comprising a chelating compound or components capable of chelating a [~~radioactive~~] metal or metal ion and providing a detectable [~~radioactive~~] signal, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to PM directly or through a linkage group, and such covalent attachment does not substantially interfere with double helix formation or nucleic acid hybridization; provided that when said nucleotide or nucleotide analog (iii) is attached to an oligoribonucleotide or a polyribonucleotide, and provided that when Sig is attached through a chemical linkage to a terminal PM at the 3' position of a terminal ribonucleotide, said chemical linkage is not obtained through a [~~2',3'~~] 2', 3' vicinal oxidation of a 3' terminal ribonucleotide previously attached to said oligoribonucleotide or polyribonucleotide; and

Filed: June 7, 1995

Marked-Up Version Of The Amended Claims

Page 12 [Exhibit A To Second Supplemental Amendment (Following Applicants'
June 14, 2001 Amendment For The Purpose Of Claim Consolidation)
-- July 12, 2001]

(b) detecting radioactively the presence of said signaling moieties Sig in any of the ~~[oligo-or]~~ oligo- or polynucleotides which have hybridized to said nucleic acid of interest by means of a ~~[radioactive]~~ metal or metal ion chelated by said chelating compounds or chelating components.

1706. (Twice Amended) A process for detecting a nucleic acid of interest in a sample, which process comprises the steps of:

(A) providing:

(i) an oligo- or polynucleotide having two segments:

(a) a first segment complementary to and capable of hybridizing to a portion of said nucleic acid of interest; and

(b) a second segment comprising at least one protein binding sequence; and

(ii) a detectable protein capable of binding to said protein binding sequence and comprising a chelating compound or chelating component capable of chelating a ~~[radioactive]~~ metal or metal ion and providing a detectable ~~[radioactive]~~ signal;

(B) contacting a sample suspected of containing said nucleic acid of interest with said oligo- or polynucleotide (i) and said detectable protein (ii) to form a complex;

(C) detecting ~~[radioactively]~~ the presence of said protein in said complex and said nucleic acid of interest by means of a ~~[radioactive]~~ metal or metal ion chelated by said chelating compound or chelating component.

Filed: June 7, 1995

Marked-Up Version Of The Amended Claims


Page 13 [Exhibit A To Second Supplemental Amendment (Following Applicants'
June 14, 2001 Amendment For The Purpose Of Claim Consolidation)

-- July 12, 2001]

1707. (Thrice Amended) A process for determining whether the number of copies of a particular chromosome in a cell is normal or abnormal, the process comprising the steps of:

contacting said cell under hybridizing conditions with one or more clones or DNA fragments, or oligo- or polynucleotides derived from said clone or clones, wherein said clones or fragments or oligo- or polynucleotides are capable of hybridizing specifically to a locus or loci of said particular chromosome or a portion thereof, wherein said clones or fragments or oligo- or polynucleotides comprise one or more detectable non-radioactive modified or labeled nucleotides or nucleotide [~~analogs,~~] analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, and wherein said detectable non-radioactive modified or labeled nucleotides or nucleotide analogs are selected from the group consisting of:

- (i) a nucleotide or nucleotide analog having the formula



wherein


PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a pyrimidine, a purine, or a 7-deazapurine base moiety or an analog of any of the foregoing thereof, and

Sig is a signaling moiety comprising a chelating compound or chelating component capable of chelating a [~~radioactive~~] metal or metal ion and providing a detectable [~~radioactive~~] signal, wherein PM is covalently attached to the SM, BASE is covalently attached to SM, and Sig is covalently attached to BASE at a position other than the C5 position when BASE is a pyrimidine moiety or an analog thereof, at a position other than the C8 position when BASE is a purine moiety or an analog thereof, and at a position other than the C7 position when BASE is a 7-deazapurine moiety or an analog thereof;

(ii) a nucleotide or nucleotide analog having the formula



wherein

PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a base moiety or base analog, and


Sig is a signaling moiety comprising a chelating compound or chelating component capable of chelating a [~~radioactive~~] metal or metal ion and providing a detectable [~~radioactive~~] signal, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to SM directly or through a linkage group; and

Filed: June 7, 1995

Marked-Up Version Of The Amended Claims

Page 15 [Exhibit A To Second Supplemental Amendment (Following Applicants'
June 14, 2001 Amendment For The Purpose Of Claim Consolidation)
-- July 12, 2001]

(iii) a nucleotide or nucleotide analog having the formula



wherein

PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a base moiety or base analog, and

Sig is a signaling moiety comprising a chelating compound or chelating component capable of chelating a ~~[radioactive]~~ metal or metal ion and providing a detectable ~~[radioactive]~~ signal, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to PM directly or through a linkage group, to permit specific hybridization of said clone or clones or DNA fragments or oligo- or polynucleotides to the locus or loci of said particular chromosome;

detecting ~~[radioactively]~~ the signal generated by said specifically hybridized clone or clones or DNA fragments or oligo- or polynucleotides by means of a ~~[radioactive]~~ metal or metal ion chelated by said chelating compound or chelating component, and determining the number of copies of said particular chromosome; and

comparing said determined number of copies of said particular chromosome with a number of copies of said particular chromosome determined for a normal cell

Filed: June 7, 1995

Marked-Up Version Of The Amended Claims

Page 16 [Exhibit A To Second Supplemental Amendment (Following Applicants'

June 14, 2001 Amendment For The Purpose Of Claim Consolidation)


-- July 12, 2001]

containing said particular chromosome, and determining whether the number of copies of said particular chromosome in said cell is abnormal.

1708. (Twice Amended) A process for identifying a chromosome of interest in a cell containing other chromosomes, the process comprising the steps of:

providing a set of clones or DNA fragments, or oligo- or polynucleotides derived from said clone or clones, wherein said clones or fragments or oligo- or polynucleotides are specifically hybridizable to a locus or loci in said chromosome of interest, wherein said clones or fragments or oligo- or polynucleotides comprise one or more detectable modified or labeled nucleotides or nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, and wherein said modified or labeled nucleotides or nucleotide analogs are selected from the group consisting of:

- (i) a nucleotide or nucleotide analog having the formula



wherein

PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a pyrimidine, a purine, or a 7-deazapurine base moiety, or a base analog of any of the foregoing, and

Sig is a signaling moiety comprising a chelating compound or chelating component capable of chelating a ~~[radioactive]~~ metal or metal ion and providing a


Filed: June 7, 1995

Marked-Up Version Of The Amended Claims

Page 17 [Exhibit A To Second Supplemental Amendment (Following Applicants'
June 14, 2001 Amendment For The Purpose Of Claim Consolidation)
-- July 12, 2001]

detectable [~~radioactive~~] signal, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to BASE at a position other than the C5 position when BASE is a pyrimidine moiety or an analog thereof, at a position other than the C8 position when BASE is a purine moiety or an analog thereof, and at a position other than the C7 position when BASE is a 7-deazapurine moiety or an analog thereof;

- (ii) a nucleotide or nucleotide analog having the formula



wherein

PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a base moiety or base analog, and


Sig is a signaling moiety comprising a chelating compound or chelating component capable of chelating a [~~radioactive~~] metal or metal ion and providing a detectable [~~radioactive~~] signal, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached SM directly or through a linkage group; and

Filed: June 7, 1995

Marked-Up Version Of The Amended Claims

Page 18 [Exhibit A To Second Supplemental Amendment (Following Applicants'
June 14, 2001 Amendment For The Purpose Of Claim Consolidation)
-- July 12, 2001]

(iii) a nucleotide or nucleotide analog having the formula



wherein

PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a base moiety or base analog, and

Sig is a signaling moiety comprising a chelating compound or chelating component capable of chelating a [radioactive] metal or metal ion and providing a detectable [radioactive] signal, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to PM directly or through a linkage group;

fixing the chromosomes from or in said cell;

contacting said fixed chromosomes under hybridizing conditions with said set of clones or DNA fragments or oligo- or polynucleotides, permitting specific hybridization of said set of clones or DNA fragments or oligo- or polynucleotides to said locus or loci in said chromosome of interest;

detecting [radioactively] by means of a [radioactive] metal or metal ion chelated by said chelating compound or chelating component any signal generated by each of said clones or DNA fragments or oligo- or polynucleotides which have specifically hybridized to said locus or loci in said chromosome of interest, and

Filed: June 7, 1995

Marked-Up Version Of The Amended Claims

Page 19 [Exhibit A To Second Supplemental Amendment (Following Applicants'
June 14, 2001 Amendment For The Purpose Of Claim Consolidation)
-- July 12, 2001]


obtaining a pattern of hybridizations between said set of clones or DNA fragments or oligo- or polynucleotides and said chromosomes; and

identifying said chromosome of interest by means of said hybridization pattern obtained.

1709. (Twice Amended) A process for identifying a plurality or all of the chromosomes in a cell of interest, the process comprising the steps of:

providing sets of clones or DNA fragments, or oligo- or polynucleotides derived from said clones, wherein each of said set of clones or DNA fragments or oligo- or polynucleotides are specifically hybridizable to a locus or loci in a chromosome of said cell of interest, wherein each of said clones or DNA fragments or oligo- or polynucleotides in said sets are labeled with a different indicator molecule and each of said clones or DNA fragments or oligo- or polynucleotides comprise one or more detectable modified or labeled nucleotides or nucleotide analogs capable of detection, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, and wherein said modified or labeled nucleotide or nucleotide analogs are selected from the group consisting of:

- (i) a nucleotide or nucleotide analog having the formula



wherein

Enz-5(D8)(C2)

Filed: June 7, 1995

Marked-Up Version Of The Amended Claims

Page 20 [Exhibit A To Second Supplemental Amendment (Following Applicants'

June 14, 2001 Amendment For The Purpose Of Claim Consolidation)

-- July 12, 2001]


PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a pyrimidine, a purine, or a 7-deazapurine base moiety, or a base analog of any of the foregoing, and

Sig is a signaling moiety comprising a chelating compound or chelating component capable of chelating a [~~radioactive~~] metal or metal ion and providing a detectable [~~radioactive~~] signal, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to BASE at a position other than the C5 position when BASE is a pyrimidine, or a pyrimidine analog, at a position other than the C8 position when BASE is a purine or a purine analog, and at a position other than the C7 position when BASE is a 7-deazapurine or a 7-deazapurine analog thereof;

(ii) a nucleotide or nucleotide analog having the formula



wherein

PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a base moiety or base analog, and

Sig is a signaling moiety comprising a chelating compound or chelating component capable of chelating a [~~radioactive~~] metal or metal ion and providing a

Filed: June 7, 1995


Marked-Up Version Of The Amended Claims

Page 21 [Exhibit A To Second Supplemental Amendment (Following Applicants'
June 14, 2001 Amendment For The Purpose Of Claim Consolidation)

-- July 12, 2001]

detectable [~~radioactive~~] signal, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to SM directly or through a linkage group; and

(iii) a nucleotide or nucleotide analog having the formula



wherein

PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a base moiety or base analog, and

Sig is a signaling moiety comprising a chelating compound or chelating component capable of chelating a [~~radioactive~~] metal or metal ion and providing a detectable [~~radioactive~~] signal, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to PM directly or through a linkage group;

fixing the chromosomes from or in said cell;


contacting said fixed chromosomes under hybridizing conditions with said sets of clones or DNA fragments or oligo- or polynucleotides, and permitting specific hybridization of said sets of clones or DNA fragments or oligo- or polynucleotides to the locus or loci in said chromosomes; and

detecting [~~radioactively~~] by means of a [~~radioactive~~] metal or metal ion chelated by said chelating compound or chelating component any signal generated by each of said different indicator molecules in said sets of clones or DNA fragments or oligo- or polynucleotides which have specifically hybridized to the locus or loci in said chromosomes, and identifying any one of the chromosomes in said cell of interest.

1710. (Twice Amended) A process for determining the number of chromosomes in an interphase cell of interest, the process comprising the steps of:

providing sets of clones or DNA fragments, or oligo- or polynucleotides derived from said clones, wherein each of said set of clones or DNA fragments or oligo- or polynucleotides are specifically complementary to or specifically hybridizable with at least one locus or loci in a chromosome of said interphase cell of interest, wherein each of said clones or DNA fragments or oligo- or polynucleotides in said sets comprise one or more detectable modified or labeled nucleotides or nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, and wherein said modified or labeled nucleotide or nucleotide analog are selected from the group consisting of:

- (i) a nucleotide or nucleotide analog having the formula



wherein

PM is a phosphate moiety or phosphate analog,

Filed: June 7, 1995

Marked-Up Version Of The Amended Claims


Page 23 [Exhibit A To Second Supplemental Amendment (Following Applicants'
June 14, 2001 Amendment For The Purpose Of Claim Consolidation)
-- July 12, 2001]

SM is a sugar moiety or sugar analog,

BASE is a pyrimidine, a purine, or a 7-deazapurine base moiety, or a base analog of any of the foregoing, and

Sig is a signaling moiety comprising a chelating compound or chelating component capable of chelating a [radioactive] metal or metal ion and providing a detectable [radioactive] signal, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to BASE at a position other than the C5 position when BASE is a, pyrimidine moiety or a pyrimidine analog, at a position other than the C8 position when BASE is a purine or a purine analog, and at a position other than the C7 position when BASE is a 7-deazapurine or a 7-deazapurine analog;

(ii) a nucleotide or nucleotide analog having the formula



wherein

PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a pyrimidine, a purine or a 7-deazapurine base moiety, or a base analog of any of the foregoing, and

Sig is a signaling moiety comprising a chelating compound or chelating component capable of chelating a [radioactive] metal or metal ion and providing a


Filed: June 7, 1995

Marked-Up Version Of The Amended Claims

Page 24 [Exhibit A To Second Supplemental Amendment (Following Applicants'
June 14, 2001 Amendment For The Purpose Of Claim Consolidation)
-- July 12, 2001]

detectable [~~radioactive~~] signal, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached SM directly or through a linkage group; and

(iii) a nucleotide or nucleotide analog, said nucleotide having the formula



wherein

PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a pyrimidine, a purine or a 7-deazapurine base moiety, or a base analog of any of the foregoing, and

Sig is a signaling moiety comprising a chelating compound or chelating component capable of chelating a [~~radioactive~~] metal or metal ion and providing a detectable [~~radioactive~~] signal, wherein PM is covalently attached to the SM, BASE is covalently attached to SM, and Sig is covalently attached to PM directly or through a linkage group;

contacting said interphase cell under hybridizing conditions with said sets of clones or DNA fragments or oligo- or polynucleotides, and permitting specific hybridization of said sets of clones or DNA fragments or oligo- or polynucleotides to any of the locus or loci in said chromosomes;

Filed: June 7, 1995

Marked-Up Version Of The Amended Claims

Page 25 [Exhibit A To Second Supplemental Amendment (Following Applicants'
June 14, 2001 Amendment For The Purpose Of Claim Consolidation)

-- July 12, 2001]

detecting [~~radioactively~~] by means of a [~~radioactive~~] metal or metal ion chelated by said chelating compound or chelating component any signals generated by each of said sets of clones or DNA fragments or oligo- or polynucleotides specifically hybridized to the locus or loci in said chromosomes, to obtain a pattern of generated signals; and comparing each generated signal with other generate signals in said pattern, and determining the number of chromosomes in said interphase cell of interest.

1711. (Twice Amended) A process for preparing a labeled oligo- or polynucleotide of interest, comprising the steps of:

(A) providing either:

(1) one or more detectable chemically modified or labeled nucleotides or nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA or an oligo- or polynucleotide of interest, alone or in conjunction with one or more other modified or unmodified nucleic acids selected from the group consisting of nucleotides, oligonucleotides and polynucleotides, wherein said other modified or unmodified nucleic acids are capable of incorporating into an oligo- or polynucleotide of interest, and wherein said chemically modified or labeled nucleotides or nucleotide analogs comprise one or more signaling moieties comprising a chelating compound or chelating component capable of chelating a radioactive metal and providing a detectable radioactive signal, or

Filed: June 7, 1995

Marked-Up Version Of The Amended Claims

Page 26 [Exhibit A To Second Supplemental Amendment (Following Applicants'

June 14, 2001 Amendment For The Purpose Of Claim Consolidation)

-- July 12, 2001]

(2) an oligo- or polynucleotide of interest comprising one or more of said detectable chemically modified or labeled nucleotides or nucleotide analogs, alone or in conjunction with one or more other modified or unmodified nucleic acids selected from the group consisting of nucleotides, oligonucleotides and polynucleotides,

wherein said chemically modified or labeled nucleotides or nucleotide analogs are modified on at least one of the sugar moiety, the sugar analog, the phosphate moiety, the phosphate [moiety] analog, the base moiety or the base analog, and are selected from the group consisting of:

(i)

PM—SM—BASE—Sig

wherein

PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a pyrimidine, a purine or a 7-deazapurine base moiety, or a base analog of any of the foregoing, and

Sig is a signaling moiety comprising a chelating compound or chelating component capable of chelating a [radioactive] metal or metal ion and providing a detectable [radioactive] signal, and

wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to BASE directly or through a linkage group at a position other than the C5 position when BASE is a pyrimidine moiety or an analog thereof, at a position other than the C8 position when BASE is a purine moiety or

Filed: June 7, 1995

Marked-Up Version Of The Amended Claims

Page 27 [Exhibit A To Second Supplemental Amendment (Following Applicants'
June 14, 2001 Amendment For The Purpose Of Claim Consolidation)
-- July 12, 2001]

an analog thereof, and at a position other than the C7 position when BASE is a 7-deazapurine moiety or an analog thereof;

(ii)

Sig

|

PM—SM—BASE

wherein

PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a pyrimidine, a purine or a 7-deazapurine base moiety, or a base analog of any of the foregoing, and

Sig is a signaling moiety comprising a chelating compound or chelating component capable of chelating a [radioactive] metal or metal ion and providing a [radioactive] signal, and wherein said PM is covalently attached to SM, said BASE is covalently attached to SM, and Sig is covalently attached to SM directly or through a linkage group; and

(iii)

Sig—PM—SM—BASE

wherein

PM is a phosphate moiety or phosphate analog,

SM is a sugar moiety or sugar analog,

BASE is a pyrimidine, a purine or a 7-deazapurine base moiety, or a base analog of any of the foregoing, and

Sig is a signaling moiety comprising a chelating compound or chelating component capable of chelating a [radioactive] metal or metal ion and providing a

Filed: June 7, 1995

Marked-Up Version Of The Amended Claims

Page 28 [Exhibit A To Second Supplemental Amendment (Following Applicants'

June 14, 2001 Amendment For The Purpose Of Claim Consolidation)

-- July 12, 2001]

detectable [~~radioactive~~] signal; and wherein PM is covalently attached to SM, BASE is covalently attached SM, and Sig is covalently attached to PM directly or through a linkage group, provided that when said nucleotide or nucleotide analog (iii) is attached to an oligoribonucleotide or a polyribonucleotide, and provided that when Sig is attached through a chemical linkage to a terminal PM at the 3' position of a terminal ribonucleotide, said chemical linkage is not obtained through a [~~2',3'~~]
2', 3' vicinal oxidation of a 3' terminal ribonucleotide previously attached to said oligoribonucleotide or polyribonucleotide; and said oligo- or polynucleotide of interest; and

(B) either incorporating said one or more modified or labeled nucleotides or nucleotide analogs (A)(1) into said oligo- or polynucleotide, and preparing a labeled oligo- or polynucleotide of interest, or preparing said oligo- or polynucleotide of interest from said oligo- or polynucleotide recited in step (A)(2) above.

* * * * *